✦ LIBER ✦

Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients

✍ Scribed by Paola Gaviani; A. Salmaggi; A. Silvani

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 119 KB
Volume: 104
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-010-0515-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Salvage chemotherapy with procarbazine a

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients

✍ Antonio Silvani; Elena Lamperti; Paola Gaviani; Marica Eoli; Anna Fiumani; Andre 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 95 KB

Salvage chemotherapy with procarbazine a

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients

✍ Antonio Silvani; Elena Lamperti; Paola Gaviani; Marica Eoli; Anna Fiumani; Andre 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 88 KB

Salvage chemotherapy with procarbazine a

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients

✍ Antonio Silvani; Elena Lamperti; Paola Gaviani; Marica Eoli; Anna Fiumani; Andre 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 224 KB

Temozolomide in combination with fotemus

Temozolomide in combination with fotemustine in patients with metastatic melanoma

✍ Faruk Tas; Hakan Camlica; Erkan Topuz 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 269 KB

A new schedule of fotemustine in temozol

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma

✍ Raffaele Addeo; Michele Caraglia; M. Serena De Santi; Liliana Montella; Alberto 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 199 KB

Salvage chemotherapy with cyclophosphami

Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme

✍ Marc C. Chamberlain; Denice D. Tsao-Wei 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

## Abstract ## BACKGROUND The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide‐refractory glioblastoma multiforme was to evaluate 6‐month progression‐free survival (PFS). ## METHODS Forty patients (28 men and 12